Navelbine (Vinorelbine Tartrate)

Vinorelbine tartrate interferes with microtubule assembly by binding to tubulin, preventing the formation of the mitotic spindle. This halts cell division in the M phase, leading to programmed cell death (apoptosis) of rapidly proliferating cancer cells.

The specific dose of Navelbine is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal and hepatic function, and treatment protocol. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for vinorelbine tartrate in pregnancy and lactation are limited. The drug is generally contraindicated in pregnancy because of potential fetal harm, and breastfeeding is not recommended while receiving treatment. Clinicians should discuss risks and alternatives with patients.

To request Navelbine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Vinorelbine belongs to the Vinca alkaloid class, similar to vincristine and vinblastine, but it has a distinct toxicity profile with relatively lower neurotoxicity. Compared with taxanes, vinorelbine offers an alternative mechanism of microtubule inhibition and may be preferred in patients who cannot tolerate taxane‑related side effects.

Navelbine should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining a stable ambient environment helps preserve the drug’s potency and safety throughout its shelf life.

Navelbine is supplied for oral administration. The tablets (or capsules) are taken with water, usually on an empty stomach, following the dosing schedule prescribed by the oncologist. Patients should not crush or chew the dosage form unless directed by a healthcare professional.

The most serious risks include severe neutropenia leading to infection, febrile neutropenia, pulmonary toxicity such as interstitial pneumonitis, and rare but life‑threatening allergic reactions. Prompt medical attention is required if patients develop fever, respiratory symptoms, or signs of an allergic response.

Navelbine is contraindicated in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, those with uncontrolled severe infections, and individuals with significant bone‑marrow suppression. Caution is also advised for patients with severe hepatic impairment or pre‑existing pulmonary disease.